Drug major Lupin on Wednesday said it has completed the acquisition of privately-held, US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS).
Lupin had announced the acquisition on July 23, 2015. The acquisition enhances the company’s scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics, Lupin said in a statement. “The GAVIS portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as specialty pipeline,” Lupin CEO Vinita Gupta said. GAVIS brings to Lupin a highly skilled US-based manufacturing and research organisation which would complement its Florida-based R&D centre for inhalation products.